Evidence map›Paper›PMID 40303366›Full record

ArticleFrontiers in medicine2025

Immunosenescence markers in T- and NK-cells according to the CD4/CD8 ratio in successfully treated people living with HIV.

Matteo Vassallo, Jacques Durant, Sami Addou, Michel Ticchioni, Roxane Fabre, David Chirio, Alissa Naqvi, Eric Cua, Leslie Ameil, Maeva Godemert and 2 more

Abstract read
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Matteo VassalloInternal Medicine/Infectious Diseases Department, Cannes, France.
Jacques DurantInfectious Diseases Department, University of Nice, Nice, France.
Sami AddouDepartment of Immunology, University of Nice, Nice, France.
Michel TicchioniDepartment of Immunology, University of Nice, Nice, France.
Roxane FabreDepartment of Public Health, University of Nice, Nice, France.
David ChirioInfectious Diseases Department, University of Nice, Nice, France.
Alissa NaqviInfectious Diseases Department, University of Nice, Nice, France.
Eric CuaInfectious Diseases Department, University of Nice, Nice, France.
Leslie AmeilInfectious Diseases Department, University of Nice, Nice, France.
Maeva GodemertClinical Research Department, University of Nice, Nice, France.
Christian PradierDepartment of Public Health, University of Nice, Nice, France.
Michel CarlesInfectious Diseases Department, University of Nice, Nice, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The CD4/CD8 ratio has emerged as a useful indicator of immune dysfunction and comorbid conditions in people living with HIV (PLWH). However, its optimal cut-off value is unclear. We explored the correlation between the CD4/CD8 ratio, immunosenescence markers and comorbid conditions. Methods: We prospectively included PLWH on successful and stable ART (antiretroviral therapy) > 60 years old and receiving either BIC/FTC/TAF or DTG/3TC, in Nice, France. HIV-negative healthy subjects were included as controls. We measured T-cell subsets (naïve, central memory, effector memory and terminally differentiated cells) and the distribution of KLRG1 + CD57+ senescent cells. We correlated CD4/CD8 ratio, background measurements and comorbid conditions. Results: We included 68 PLWH (median age 69 years, 31 years on ART, median CD4/CD8 ratio 0.76). PLWH had higher levels of senescence markers than controls ( Conclusion: PLWH on successful ART display elevated immunosenescence markers, mainly on CD8+ T-cells. A CD4/CD8 cut-off value below 0.4 showed the strongest association with immune dysfunction, including NK+ cells. Such results could be useful for identifying patients requiring closer follow-up and screening for complications.

Indexed as

CD4/CD8 ratiocomorbidityHIVimmune activationimmunosenescence

Identifiers

PMID40303366
PMCPMC12037392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.